FDA Comments on Recently Released Rare Disease Guidance for Industry
Jonathan Goldsmith, M.D., F.A.C.P., FDA’s Associate Director, Rare Diseases Program, Center for Drug Evaluation and Research, comments on...
top of page
Recent Posts
bottom of page
top of page
Recent Posts
bottom of page